A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2018
At a glance
- Drugs Spartalizumab (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 06 Feb 2018 Planned End Date changed from 28 Jun 2018 to 23 May 2019.
- 06 Feb 2018 Planned primary completion date changed from 1 May 2018 to 23 May 2019.